[Recent advances in theragnostics and new perspectives in molecular radiotherapy].

Authors

Lavinia Vija, Clément Bailly, Fréderic Courbon, Emmanuel Deshayes

Published in

Bulletin du cancer. Sep 25, 2026. Epub Sep 25, 2026.

Abstract

Theragnostics represents an attractive approach in nuclear medicine as it combines diagnostics and therapy using the same molecular target by switching gamma- or positron-emitting radionuclides with alpha, beta- or Auger electron emitting radionuclides. Radioligand therapy targeting PSMA and somatostatin receptors already demonstrated a significant clinical benefit with lots of innovative clinical trials looking for new perspectives of efficacy during different moments of the disease history or searching for new therapeutic indications. Looking for effective and simple biomarkers to assess therapy efficacy or detect risk of early relapse, identify the best dosimetric approach and understand complex radiobiological effects are some challenges to approach. New radionuclides have emerged including alpha emitters, such as Ac-225, Pb-212 or At-211; they are currently being evaluated either alone or in combination therapies in several types of cancers in early phase trials. More than 270 clinical trials are at present ongoing in theragnostics, raising new questions and new expectations in the field of nuclear medicine as a precision medicine branch of oncology.

PMID:
42791112
Bibliographic data and abstract were imported from PubMed on 26 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.